Allied Market Research

2024

Human Insulin Market

Human Insulin Market Size, Share, Competitive Landscape and Trend Analysis Report by Product Type (HI DRUGS, HI DELIVERY DEVICES), by DRUG TYPE (HI BIOLOGICS, HI BIOSIMILARS AND ANALOGS), by DRUG BRAND (HI BIOLOGICS, HI BIOSIMILARS AND ANALOGS), by DELIVERY DEVICE (SYRINGES, PENS, PEN NEEDLES) and by APPLICATION (TYPE I DIABETES, TYPE II DIABETES): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. The global human insulin market is expected to grow at healthy CAGR during the forecast period due to high prevalence of diabetes, worldwide. In-depth analysis of the global human insulin market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities. Competitive landscape section focuses on key leaders within the global human insulin market and their major growth strategies. Detailed analysis of segments helps in understanding market dynamics and would be beneficial for market professionals.

The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. However, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin.

Global Human Insulin Market by Types

The global human insulin market is segmented by product type into Traditional and Modern Human Insulin. Traditional Human Insulin is segmented as Premixed, Intermediate Acting and Short Acting Human Insulin, whereas Modern Human Insulin includes Premixed, Long Acting and Rapid Acting types. Long acting modern insulin and premixed modern insulin are the fastest growing categories of this segment.  

Global Human Insulin Market by Brands

According to the brands available into the market, the global human insulin market is classified as traditional and modern human insulin brands. Traditional brands include Humulin, Actrapid and Insuman, whereas, modern brands include Humalog, Novomix, Novorapid, Lantus, Levemir and Apidra. Over the past few years, biosimilars has gained popularity in comparison to branded drugs. Basalog, Wosulin and Glaritus are the biosimilars available in Asia-Pacific region. Amongst traditional and modern brands, Lantus holds the largest market share, whereas, Levemir and Apidra are the fastest growing insulin drugs. 

Global Human Insulin Market by Geography

Geographically, global human insulin market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global human insulin market owing to high prevalence of diabetes and technological advances in effective insulin delivery. Asia-Pacific and LAMEA are the fastest growing geographic segments due to high diabetes incidences, government support and improving healthcare conditions.  

 
Competitive Landscape

Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt are some of the key players of global human insulin market. Manufacturers are focusing to develop the advanced techniques of insulin delivery to gain the competitive advantage. Development of biosimilars is a booming trend in global human insulin market and Wockhardt and Biocon have launched their biosimilars products in Asia-Pacific region.

High Level Analysis 

The study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global human insulin market, their operating strategies, new launches, pipeline products and clinical trials. Porter’s Five Forces analysis has been used to determine the attractiveness of global human insulin market. Large pool of diabetic population and high cost of technology required to manufacture innovative insulin delivery devices are the factors that tend to increase the supplier’s bargaining power. High cost of down streaming process and manunufacturing complexities limit the new players in entering the market. Industrial rivalry is intense due to patent expiration of major brands and growing demand for biosimilars products.

Human Insulin Market Report Highlights

Aspects Details
Human Insulin Market By Product Type
By Product Type
  • HI DRUGS
  • HI DELIVERY DEVICES
Human Insulin Market By DRUG TYPE
By DRUG TYPE
  • HI BIOLOGICS
    • Short-Acting Biologics
    • Intermediate Acting Biologics
    • Premixed Biologics
  • HI BIOSIMILARS AND ANALOGS
    • Long-Acting Biosimilars
    • Rapid Acting Biosimilars
    • Premixed Biosimilars
Human Insulin Market By DRUG BRAND
By DRUG BRAND
  • HI BIOLOGICS
    • Humulin
    • Insuman
  • HI BIOSIMILARS AND ANALOGS
    • Lantus
    • Novorapid &Novolog
    • Humalog
    • Other
Human Insulin Market By DELIVERY DEVICE
By DELIVERY DEVICE
  • SYRINGES
  • PENS
    • Reusable Pens
    • Disposable Pens
  • PEN NEEDLES
    • Standard Pen Needles
    • Safety Pen Needles
Human Insulin Market By APPLICATION
By APPLICATION
  • TYPE I DIABETES
  • TYPE II DIABETES
Human Insulin Market By Region
By Region
  • NORTH AMERICA  (U.S, Canada, Mexico)
  • EUROPE  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • ASIA-PACIFIC  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players
Key Market Players

SANOFI S.A., JULPHAR, BIOCON LIMITED, NOVO Nordisk A/S, ALBIREO PHARMA, INC., B. BRAUN MELSUNGEN AG, YPSOMED HOLDING AG, WOCKHARDT LIMITED, BECTON, DICKINSON AND COMPANY, ELI LILLY AND COMPANY

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Human Insulin Market

Global Opportunity Analysis and Industry Forecast, 2023-2032